Alfasigma USA, Inc. the United States distributor of tegaserod, brand name Zelnorm, which is a prescription medication for some women with IBS with constipation (IBS-C),  has announced that as of June 30, 2022, it is no longer providing this medication. Alfasigma’s press release states that this decision is not due to a recall or any

April is IBS Awareness Month in many countries. During this month every year, increased and very needed attention is given to IBS and the experiences of those of us who live with it. Join IBS Impact, other affected people, families, friends, IBS and functional GI/disorder of gut-brain interaction professionals and organizations who are uniting in

Today is Veterans Day in the U.S. Thank you to all veterans and current service members for your service. Veterans who served in the Southwest Asia region at any time since 1990 are disproportionately affected by functional GI and motility disorders like IBS compared to the general population, for which FGIMDs are already common. The

The following survey on IBS experiences is open to any adult with IBS, age 18 or older and is a collaboration between the International Foundation for Gastrointestinal Disorders, a 30 year old science-based U.S. not for profit organization/charity and the online site, WebMD. The aim is to gain insights that will improve patient care for

The following survey on pandemic, COVID, and vaccine experiences among people with any chronic GI disorder, including IBS, is from the International Foundation for Gastrointestinal Disorders, a 30 year old science-based U.S. not for profit organization/charity. The survey is online, anonymous and international. Please address any questions or concerns directly to IFFGD as the originator

The following focus group is a new opportunity being established by the International Foundation for Gastrointestinal Disorders (IFFGD), a 30 year old U.S. not for profit organization focused on various gastrointestinal disorders, including IBS and other disorders of brain-gut interaction/functional gastrointestinal disorders. Below is the text of the announcement exactly as received from IFFGD. IBS

April is IBS Awareness Month in many countries. During this month every year, increased and very needed attention is given to IBS and the experiences of those of us who live with it. Join IBS Impact, other affected people, families, friends, IBS and functional GI/disorder of gut-brain interaction professionals and organizations who are uniting in

The American Journal of Gastroenterology has published the American College of Gastroenterology’s  newly updated guidelines for the management of irritable bowel syndrome (IBS) in its December 2020 issue. Seven named authors from the fields of gastroenterology  and gastrointestinal health psychology, represent five United States universities or academic medical centers that are leaders in IBS research.

Beginning in 2007, the International Foundation for Gastrointestinal Disorders (IFFGD) began conducting a multi-year comprehensive survey of people with IBS, their experiences and unmet needs. This survey attracted a large number of responses internationally and its insights have been important contributions to IBS research, medical care and support systems since then. Now in 2020, IFFGD

This past week, the U.S Food and Drug Administration (FDA) approved the sale and distribution of a new medication for irritable bowel syndrome with constipation (IBS-C), tenapanor, to be known by the brand name Ibsrela. Tenapanor, a 50 mg. daily oral medication is approved for adults. It has not been approved for youth under the